Lifesci Capital Issues Negative Estimate for Abivax Earnings

Abivax SA Sponsored ADR (NASDAQ:ABVX) – Investment analysts at Lifesci Capital decreased their FY2025 earnings per share (EPS) estimates for shares of Abivax in a report issued on Thursday, January 8th. Lifesci Capital analyst S. Slutsky now expects that the company will earn ($5.23) per share for the year, down from their prior forecast of ($3.47). The consensus estimate for Abivax’s current full-year earnings is ($2.83) per share.

Abivax (NASDAQ:ABVX) last announced its quarterly earnings data on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The company had revenue of ($4.92) million for the quarter.

ABVX has been the subject of several other reports. Guggenheim reiterated a “buy” rating and set a $175.00 price objective on shares of Abivax in a report on Thursday, December 18th. BTIG Research boosted their target price on shares of Abivax from $120.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Wall Street Zen downgraded shares of Abivax from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. Citizens Jmp lifted their price objective on shares of Abivax from $114.00 to $131.00 and gave the company a “market outperform” rating in a research note on Tuesday, December 16th. Finally, Barclays assumed coverage on shares of Abivax in a report on Monday, October 13th. They issued an “overweight” rating and a $142.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Abivax presently has an average rating of “Moderate Buy” and an average price target of $135.08.

Abivax Trading Up 1.4%

Shares of NASDAQ:ABVX opened at $119.64 on Monday. The firm has a fifty day moving average of $120.97 and a two-hundred day moving average of $87.21. The company has a quick ratio of 7.86, a current ratio of 7.86 and a debt-to-equity ratio of 0.03. Abivax has a 12-month low of $4.77 and a 12-month high of $148.83. The firm has a market capitalization of $9.32 billion, a P/E ratio of -28.62 and a beta of 0.68.

Institutional Trading of Abivax

Several large investors have recently modified their holdings of ABVX. Avanza Fonder AB bought a new position in Abivax in the 4th quarter worth $168,000. QP Wealth Management LLC acquired a new stake in shares of Abivax in the fourth quarter valued at about $745,000. Avior Wealth Management LLC bought a new position in shares of Abivax in the fourth quarter worth about $377,000. Union Bancaire Privee UBP SA acquired a new position in shares of Abivax during the 4th quarter worth about $67,000. Finally, Tudor Investment Corp ET AL acquired a new position in shares of Abivax during the 3rd quarter worth about $2,792,000. 47.91% of the stock is owned by institutional investors.

Trending Headlines about Abivax

Here are the key news stories impacting Abivax this week:

• Positive Sentiment: Media reports that Eli Lilly is interested in a multi?billion euro/dollar bid for Abivax have driven sharp buying interest; renewed M&A chatter is the main catalyst lifting the stock. Abivax stock rockets 30% on Eli Lilly takeover speculation
• Positive Sentiment: Major press coverage that cited a possible ~$17.5B bid (and broad M&A interest) amplified buying momentum and volatility in early trading. Abivax Surges on Report Ely Lily is Preparing $17.5 Billion Bid
• Positive Sentiment: An analyst price?target increase provides additional support for the rally (higher target can validate upside expectations). Abivax (NASDAQ:ABVX) Price Target Raised to $145.00
• Positive Sentiment: Fundamental bull case reiterated: a Seeking Alpha piece reminds investors that obefazimod’s strong ulcerative colitis data and upcoming catalysts (Phase 3 maintenance topline, potential NDA/MAA filings, Phase 2b Crohn’s results) make Abivax an attractive stand?alone investment and plausible M&A target. Abivax: Don’t Just Buy The Rumor, Buy The Fundamentals
• Neutral Sentiment: Short interest rose in December to ~2.91M shares (~3.7% of float), implying some bearish positioning that could amplify moves in either direction; short?interest ratio ~1.7 days. (Data summary)
• Neutral Sentiment: January short?interest figures reported as zero appear erroneous or incomplete — treat recent short?interest updates with caution until exchanges confirm accurate filings. (Data summary)
• Negative Sentiment: French finance ministry said it has received no investment?approval request for Abivax and had no contact with Eli Lilly, directly undercutting the takeover narrative and adding uncertainty about deal probability. France has had no request for investment approval in biotech Abivax – official
• Negative Sentiment: Lifesci Capital trimmed earnings estimates for Abivax, which could temper some expectations around near?term financial forecasts and valuations. Lifesci Capital Decreases Earnings Estimates for Abivax

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.